MedTrace Logo

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

NCT00151476 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2024-09-04

Study results available
· View outcomes & findings →

Summary

This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib.

Both retrospective and prospective data will be utilized. No sampling methods apply.

Conditions

  • Familial Adenomatous Polyposis (FAP)

Interventions

DRUG

Celecoxib

800 mg total daily dosing

OTHER

Routine Medical Care

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Canada
  • Denmark
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00151476 on ClinicalTrials.gov